Acta Scientific Otolaryngology (ASOL) (ISSN: 2582-5550)

Case Report Volume 4 Issue 8

Effectiveness of Convalescent Plasma Therapy in Critically Ill COVID-19 Patient: A Case Report

Nezar Yaseen Albar1, Ayman Khater2, Naif Yaseen Albar3* and Ibrahim Galal4

1Department of Internal Medicine, Endocrinology, Nostalgia Clinic, Jeddah, Saudi Arabia
2Department of Pulmonology, Samir Abbas Hospital, Jeddah, Saudi Arabia
3Department of Otorhinolaryngology, Head and Neck Surgery, King Abdulaziz University College of Medicine. Rabigh, Jeddah, Saudi Arabia
4Department of ICU, Samir Abbas Hospital, Jeddah, Saudi Arabia

*Corresponding Author: Naif Yaseen Albar, Department of Otorhinolaryngology, Head and Neck Surgery, King Abdulaziz University College of Medicine. Rabigh, Jeddah, Saudi Arabia.

Received: June 24, 2022; Published: July 21, 2022

Abstract

Background: COVID-19 is a pandemic with no specific therapeutic agents yet approved. Presenting our experience with the clinical efficacy of convalescent plasma (CP) therapy in a critically ill non-responsive COVID-19 patient.

Case Summary: A diabetic hypertensive 70-year-old patient presented to ER with dyspnea, SO2 90% RA and low-grade fever along with COVID-19 positive swab by PCR, and bilateral fine basal crackles, chest CT shows ground glass opacities (GGOs) in the right upper Lobe, CRP 3 mg/dl and IL-6 18 pg/ml. After initial 3 days stay in ICU, condition improved on oral Favipiravir, Azithromycin and Oseltamivir, and IV Ceftriaxone and IM dexamethasone. One week after initial discharge from ICU, condition gradually deteriorated with no response to Tocilizumab administration then pulse therapy methyl prednisolone and Remdesivir. Patient readmitted to ICU and treatment with CP was started with 2 units derived from a recently recovered single donor with plasma SARS-CoV-2 anti-S1/S2 IgG antibodies of 20 AU/mL. After initial improvement patient was discharged from ICU, but then condition deteriorated again with dramatic rise of IL-6. After extra 2 doses of Convalescent Plasma but this time derived from another donor with higher neutralizing activity as inferred by a higher plasma anti-S1/S2 IgG antibodies level of 39 AU/mL, patient condition improved dramatically with SO2 90-92% on RA sitting position. He was then finally discharged on home medication and domiciliary oxygen during effort and sleep.

Discussion: This case supports the role of CP with sufficient neutralizing capacity, as an effective treatment for critically ill COVID-19 patients.

Keywords: COVID-19; SARS-CoV-2; Convalescent Plasma (CP)

References

  1. Chen N., et al. “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study”. Lancet (London, England) 395.10223 (2020): 507-513.
  2. Cheng Y., et al. “Use of convalescent plasma therapy in SARS patients in Hong Kong”. European Journal of Clinical Microbiology and Infectious Diseases 1 (2005): 44-46.
  3. Duan K., et al. “Effectiveness of convalescent plasma therapy in severe COVID-19 patients”. 117.17 (2020): 9490-9496.
  4. Hung IF., et al. “Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection”. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 4 (2011): 447-456.
  5. Mair-Jenkins J., et al. “The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis”. The Journal of Infectious Diseases1 (2015): 80-90.
  6. Chen L., et al. “Convalescent plasma as a potential therapy for COVID-19”. The Lancet Infectious Diseases4 (2020): 398-400.
  7. Joyner MJ., et al. “Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience”. medRxiv : The Preprint Server for Health Sciences (2020): 2020.08.12.20169359.
  8. Klassen SA., et al. “The Effect of Convalescent Plasma Therapy on COVID-19 Patient Mortality: Systematic Review and Meta-analysis”. medRxiv : The Preprint Server for Health Sciences (2021): 2020.07.29.20162917.
  9. Joyner MJ., et al. “Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients”. Mayo Clinic Proceedings 9 (2020): 1888-1897.
  10. Shen C., et al. “Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma”. JAMA 16 (2020): 1582-1589.
  11. Salazar E., et al. “Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality”. The American Journal of Pathology11 (2020): 2290-2303.
  12. Tanne JH. “Covid-19: FDA approves use of convalescent plasma to treat critically ill patients”. BMJ (Clinical research ed) 368 (2020): m1256.
  13. Meyer B., et al. “Validation of a commercially available SARS-CoV-2 serological immunoassay”. Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases10 (2020): 1386-1394.
  14. Meyer B and Reimerink J. “Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)”. Emerging Microbes and Infections1 (2020): 2394-2403.
  15. Luchsinger LL., et al. “Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients”. Journal of Clinical Microbiology12 (2020).
  16. Valdivia A., et al. “Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays”. European Journal of Clinical Microbiology and Infectious Diseases3 (2021): 485-494.
  17. Zhu Z., et al. “Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019”. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases 95 (2020): 332-339.
  18. Liu B., et al. “Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?” Journal of Autoimmunity 111 (2020): 102452.
  19. Niculet E., et al. “Multifactorial expression of IL-6 with update on COVID-19 and the therapeutic strategies of its blockade (Review)”. Experimental and Therapeutic Medicine3 (2021): 263.

Citation

Citation: Nezar Yaseen Albar., et al. “Effectiveness of Convalescent Plasma Therapy in Critically Ill COVID-19 Patient: A Case Report".Acta Scientific Otolaryngology 4.8 (2022): 27-32.

Copyright

Copyright: © 2022 Nezar Yaseen Albar., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate34%
Acceptance to publication20-30 days
Impact Factor0.871

Indexed In







News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US